CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(04): 309-312
DOI: 10.4103/0971-5851.125252
CASE REPORT

Primary mediastinal seminoma; resistance and relapse: An aggressive entity

Ankita Nachankar
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Rahul Krishnatry
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Amit Joshi
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Jai Prakash Agarwal
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations

Abstract

Seminoma is one of the most radio and chemo sensitive tumors. Aggressive variant of primary mediastinal seminoma (PMS) are rarely described in the literature. We here discuss an interesting case of young male (22 years) presenting with superior vena cava syndrome due to PMS that showed poor response to conventional platinum based chemotherapy and radiotherapy. Furthermore, with a short disease free interval (one year) relapsed at unusual sites of bone and soft-tissue deposits in check. This emphasizes the importance of identifying methods to pre-screen such aggressive variants for more effective treatment options.



Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis. J Clin Oncol 2002;20:1864-73.
  • 2 Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010;28:3388-404.
  • 3 Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, et al. 2-¹ 8 fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: A retrospective validation of the SEMPET trial. Ann Oncol 2012;23:59-64.
  • 4 Müller J, Schrader AJ, Jentzmik F, Schrader M. Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹ 8 F-2-fluoro-2-deoxy-D-glucose positron emission tomography - Meta-analysis of diagnostic value. Urologe A 2011;50:322-7.
  • 5 Iwasa S, Ando M, Ono M, Hirata T, Yunokawa M, Nakano E, et al. Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: Case report. Jpn J Clin Oncol 2009;39:456-9.
  • 6 Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, et al. Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas M. D. Anderson Cancer Center experience. Urol Oncol 2012;30:879-85.
  • 7 Plaza JA, Perez-Montiel D, Mayerson J, Morrison C, Suster S. Metastases to soft tissue: A review of 118 cases over a 30-year period. Cancer 2008;112:193-203.
  • 8 Rotterdam H, Slavutin L. Secondary tumors of soft tissues: An autopsy study. In: Fenoglio C, editor. Progress in Surgical Pathology. Vol. 3. New York: Masson; 1981. p. 147-70.
  • 9 Bilici A, Ustaalioglu BB, Seker M, Kayahan S. Case report: Soft tissue metastasis from immature teratoma of the testis: Second case report and review of the literature. Clin Orthop Relat Res 2010;468:2541-4.
  • 10 Byun JC, Choi IJ, Han MS, Lee SC, Roh MS, Cha MS. Soft tissue metastasis of an immature teratoma of the ovary. J Obstet Gynaecol Res 2011;37:1689-93.
  • 11 Zohar Y, Ben-Tovim R, Gal R, Laurian N. Metastatic carcinoma of oral soft tissue. Head Neck Surg 1985;7:484-6.
  • 12 Ruf CG, Linbecker M, Port M, Riecke A, Schmelz HU, Wagner W, et al. Predicting metastasized seminoma using gene expression. BJU Int 2012;110:E14-20.
  • 13 Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 2009;27:2129-36.
  • 14 Pectasides D, Nikolaou M, Pectasides E, Koumarianou A, Valavanis C, Economopoulos T. Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma. Anticancer Res 2008;28:2317-20.
  • 15 Braquet P, Chapelle A, Jorgensen C, Pers YM. Unusual seminoma revealed by bone metastasis. Joint Bone Spine 2011;78:644-5.